glucagon has been researched along with 1-(3-chlorophenyl)piperazine in 1 studies
Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (1-(3-chlorophenyl)piperazine) | Trials (1-(3-chlorophenyl)piperazine) | Recent Studies (post-2010) (1-(3-chlorophenyl)piperazine) |
---|---|---|---|---|---|
26,039 | 1,498 | 3,054 | 833 | 142 | 87 |
Protein | Taxonomy | glucagon (IC50) | 1-(3-chlorophenyl)piperazine (IC50) |
---|---|---|---|
Beta-1 adrenergic receptor | Homo sapiens (human) | 2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sugimoto, Y; Yamada, J | 1 |
1 other study(ies) available for glucagon and 1-(3-chlorophenyl)piperazine
Article | Year |
---|---|
The 5-HT(2C/2B) receptor agonist, m-chlorophenylpiperazine, increases plasma glucagon levels in rats.
Topics: Adrenal Medulla; Animals; Blood Glucose; Dose-Response Relationship, Drug; Glucagon; Ketanserin; Male; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Ritanserin; Serotonin Antagonists; Serotonin Receptor Agonists; Time Factors | 2000 |